Introduction: The use of growth hormone (GH) treatment in GH deficiency (GHD) continues to increase. However, individual controlled trials of the efficacy and safety of GH have involved relatively few patients and yielded variable results. We seek to analyze the overall effect of GH treatment on various parameters by performing a contemporary meta-analysis of the efficacy and safety of GH administration. Methods: Meta-analysis of 48 blinded, placebo controlled, randomized clinical studies of GH treatment in GHD adults published up to June 2011 was performed. Analyzed variables included anthropomorphic measurements (waist-hip ratio (WHR), lean body mass (LBM)/fat free mass (FFM), trunk fat (TrF), total body water (TBW), fat mass (FM), and body mass index (BMI)); cardiovascular (CV) parameters (systolic/diastolic blood pressure (SBP, DBP), heart rate (HR), stroke volume (SV), LDL, HDL, total cholesterol (TChol), triglycerides (TG), apolipoprotein B (ApoB), C-reactive protein (CRP)); and diabetes parameters (fasting insulin and glucose, hemoglobin A1c (HgbA1c)). Effect sizes (ES) were used to determine significance and weighted mean differences between GH and control were used to quantify size of effect. Results: 2231 adults with growth hormone deficiency were included. Significant beneficial changes resulting from GH administration were observed in the following variables: anthropomorphic-WHR, FM, LBM, FFM, TBW; cardiovascular-LDL, HDL, TChol, ApoB, CRP; significant adverse changes were seen in diabetic parameters-fasting insulin, fasting glucose, and HgbA1c. Compared to prior meta-analyses, larger ESs were observed for LDL, HDL, total cholesterol, fasting insulin and fasting glucose levels. Conclusions: GH administration in GHD adults results in improvement in anthropomorphic parameters, as well as CV parameters, but with worsening of diabetes markers. Data on long-term safety, including on CV effects and malignancy, as well as data assessing the role of GH replacement in combination with testosterone replacement continue to be sparse.
Introduction
The use of growth hormone (GH) for the treatment of growth hormone deficiency (GHD), a form of hypopituitarism, continues to increase. However, most studies assessing the efficacy and safety of GH involve relatively few patients. Growth hormone deficiency in adults is associated with an increased mortality rate [1, 2] . Previous studies have shown that GHD affects numerous health parameters including anthropomorphic and cardiovascular (CV) parameters, glucose and insulin sensitivity, and overall quality of life [3] . In addition, GH use by individuals without GHD continues, though no controlled studies are available to assess the effects in this setting, despite reports of deleterious effects of GH and/or anabolic steroids in these individuals [4] [5] [6] [7] .
Clinical trials have shown that GH therapy improves body fat parameters in the GHD population through an increase in lean body mass and a decrease in serum lipids, with variable effect sizes on these parameters observed between studies [8] . While this variability may be attributable to differences in the degree of GH deficiency, GH dose, therapy duration, sample size and/or composition, further evaluation in the form of additional controlled studies or meta-analyses is needed to clarify these points. Meta-analyses evaluating the effects of GH therapy are available, although numerous additional controlled studies have been published since the last significant report [9] [10] [11] [12] . Moreover, recent studies have begun exploring the synergistic role of GH therapy in combination with androgen therapy in the healthy elderly population, which is likely to have future impact on the care of this population [13, 14] . Thus, in light of the growing use of GH therapy and the addition of numerous controlled
Materials and Methods

Data Sources and Searches
We searched the Medline (Ovid), Biosis, and EMBASE electronic databases from their years of inception to June 2011 for reports containing the following keywords: growth hormone (GH), therapy, treatment, and growth hormone deficiency. The search strategy was limited by study design to include only adults (19+ years old) in randomized, placebo-controlled clinical trials.
Study Selection
Inclusion of candidate studies by two of the authors (AWP, WSL) was based on the ability of the abstract and then the actual study to meet the inclusion criteria. We identified 45 randomized, blinded, placebo-controlled trials (RBPCTs) involving patients 19 years or older with GHD corresponding to GH levels < 5 µg/L after stimulation testing using insulin and/or arginine , as recommended by the consensus guidelines for the diagnosis and treatment of adults with GHD [15] and also included 3 crossover studies that had been utilized in a prior meta-analysis for comparison [9, 18, 51, 60] (Figure 1 We also identified 2 RBPCTs assessing the effects of testosterone (T) and GH in order to compare these variables directly [13, 14] . This study targeted variables which represent the effects of GH on anthropomorphic and CV parameters and have been frequently reported in prior studies examining the effects of GH: insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP3), waist-to-hip ratio (WHR), lean body mass (LBM), fat free mass (FFM), trunk fat (TrF), total body water (TBW), fat mass (FM), body mass index (BMI), diastolic blood pressure (DBP), systolic blood pressure (SBP), heart rate (HR), stroke volume (SV), triglycerides (TG), high-density lipoprotein (HDL), lowdensity lipoprotein (LDL), total cholesterol (TChol), apolipoprotein B (ApoB), C-reactive protein (CRP), E (Early (diastolic))/A (late, (Atrial) filling) ratio (EAR), fractional shortening (FS), left ventricular mass (LVM), fasting glucose, fasting insulin, and hemoglobin A1c (HgbA1c).
Data Extraction and Quality Assessment
Summary data reflecting net effects on each variable studied from each report were extracted by a single author (WSL) into a standard form and included number of subjects, subject age, sex, cause of GHD, GHD diagnostic modality, GH dose, duration of GH therapy, GH dosing frequency, adverse effects, study design, randomization method, blinding, and statistical methods, outcome measures, subjects lost to follow-up, and baseline and follow-up means and standard deviations (SD) for each variable.
Data Synthesis and Analysis
For primary analyses of outcome measures, we calculated standardized effect sizes (ES) using Hedges' g via a random-effects model for each trial, since such a model incorporates statistical heterogeneity and provides a more conservative estimate of pooled effect size than a fixedeffects model [65] . The ES was calculated as the mean difference (GH minus placebo) in the changes (follow-up minus baseline) for each outcome measure divided by the estimated variance of changes in the two groups, and weighted by the reciprocal of the variance. The variance-weighted mean difference (WMD) was calculated for each variable in order to determine absolute effects of GH administration on variables in the units of each variable. Heterogeneity between studies was assessed using a Q parameter as defined by Cochran [66] . Given that ES may be skewed due to the results of a single study, we performed sensitivity analysis by excluding the study with the largest sample population per outcome measured.
To determine the effects of GH dose, subject gender, GH treatment duration, and subject age, studies were grouped based on the following and meta-analysis within each group performed: GH dose-studies utilizing <0.35 U/kg/week (low dose) and ≥0.35 U/kg/week of GH (high dose); subject gender-studies involving <50% female or ≥50% female; GH treatment duration-studies with GH treatment for <6 months, or ≥6 months; subject agestudies involving patients <40 years old or ≥40 years old. To compare the effects of GH and T administration, meta-analysis of the 2 included studies was performed. All analyses were conducted using the Statistical Package for Social Sciences (SPSS) (SPSS Inc., Chicago, IL) for Windows and Apple Macintosh, and Microsoft Excel (Microsoft, Inc., Redmond, WA).
Results
A meta-analysis of 48 studies involving 2231 patients with GHD was performed to assess the effects of GH on anthropomorphic, CV, and carbohydrate metabolism parameters ( Table 1) . Results are presented in terms of effect size (ES) calculated using a random-effects model after a Q parameter calculation demonstrated minimal heterogeneity across studies, as well as in terms of the weighted mean difference (WMD) for each variable. Ninety-nine patients were lost or withdrew across all studies ( Table 1) . Causes of GHD were: 73% pituitary tumor, 11% idiopathic causes, and 16% other causes. 
Growth Hormone Serum Parameters
Data for serum parameters evaluating GH administration were obtained from 19 studies involving 983 patients. Significant positive effects on IGF-1, a surrogate marker for GH used primarily due to its significantly longer half-life, and IGFBP3, a major IGF binding protein that is used to assess GH production in concert with IGF-1, were observed (Table 2, Figure 2 ). Due to lack of standardization of IGF-1 levels to age across all studies, a comprehensive z-score analysis that accounts for the effects of GH as a function of age could not be performed.
The above data are in line with other studies demonstrating an increase in serum IGF-1 and IGFBP3 as a result of GH administration [40, 42, 52] .
Anthropomorphic Parameters
Growth hormone enhances lean body mass through skeletal muscle growth stimulation and fat loss [24, 28, 39] . We extracted data for waist-hip ratio (WHR), lean body mass (LBM)/fat free mass (FFM), trunk fat (TrF), total body water (TBW), fat mass (FM), and body mass index (BMI) from 28 studies involving 1464 patients (Table 2, Figure  2 ). Significant negative effects of GH administration were observed for WHR and FM, and significant positive effects observed for LBM, FFM, and TBW. No significant effects of GH administration were observed on TrF and BMI. Sensitivity analysis, in which the study with the largest patient population for each variable was removed from the analysis, demonstrated no significant changes in ES for all variables (Supplementary Table 1 ).
Cardiovascular Parameters
Given that GHD is associated with depressed systolic eart function and increased CV mortality, understanding h whether GH replacement improves heart function and decreases mortality risk is essential [67, 68] . We extracted data assessing systolic and diastolic blood pressure (SBP, DBP), heart rate (HR), stroke volume (SV), LDL, HDL, total cholesterol (TChol), total triglycerides (TG), apolipoprotein B (ApoB), C-reactive protein (CRP), the early to late ventricular diastolic filling (E/A) ratio (EAR), left ventricular mass (LVM) and left ventricular fractional shortening (FS) from 33 studies involving 1269 patients (Table 2, Figure 2 ). Significant negative effects of GH administration were observed on LDL, TChol, ApoB, and CRP, and a small but significant positive effect was seen on EAR and HDL cholesterol. No effect was observed for SBP, DBP, HR, SV, TG, LVM, or FS. Sensitivity analysis demonstrated significant positive effects for SV and HR, and no significant change in EAR and CRP, indicating that the contributions of individual studies were significant in the determination of our initial results (Supplementary Table 1 ). While our results with regards to the effects of GH on LDL and TChol are in line with those of a prior meta-analysis, we find no significant decrease in DBP in our study, in contrast with prior findings [9] . In addition, while a prior meta-analysis had identified an increase in SV as a function of GH administration, we find no significant effect on SV in our analysis, except when excluding the largest study analyzing SV, which evaluated 30 patients of a total of 104 evaluated for SV in our analysis (Supplementary Table  1 ) [10, 59] .
Carbohydrate Metabolism
GH is known to impair glucose tolerance and antagonize insulin action through an incompletely defined mechanism [69] . Data from 19 studies involving 913 patients were analyzed, demonstrating that GH produces a significant increase in fasting insulin, glucose and HgbA1c (Table 2, Figure 2) . These data are largely in agreement with those of prior studies. However, while our analysis demonstrates a significant increase in HgbA1c, numerous included studies found no change in HgbA1c levels [41, 52] . A sensitivity analysis demonstrated no change in significance of ESs across assayed variables (Supplementary Table 1 ) [23, 28, 33] .
Sex Steroids
Evaluation for hypogonadism and subsequent T replacement is commonplace in the aging male population, Copyright © 2012 SciRes. OJU A. W. PASTUSZAK ET AL.
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whereas testing for GHD is far less common. In addition, in individuals using anabolic steroids, it is of interest to assess whether the use of GH can offset potentially deleterious CV effects associated with steroid use, including increased LDL, decreased HDL, elevated SBP and DBP, and changes in cardiac electrophysiology and left ventricular size [70] . However, few controlled studies exist assessing the role of GH administration in the setting of T replacement. We identified 2 randomized, placebocontrolled studies involving 184 patients comparing T replacement to GH and T or GH replacement to placebo and performed a nested meta-analysis of FM and LBM, the only common variables assessed by these studies. We observed a significant negative effect of GH on FM and a significant positive effect on LBM in comparison to placebo, in agreement with our larger analysis above (Table  3) . When comparing administration of GH and T simultaneously with administration of T alone, we observed a significant negative effect of GH and T on FM but not on LBM. Finally, when comparing simultaneous GH and T administration to GH alone, we observe no significant effect of the combination on FM or LBM. Taken together these data suggest that GH has a more pronounced effect on FM and LBM than T.
Effect of GH Dose
To better define the effects of GH dose, we meta-analyzed studies segregated based on a GH dose cutoff of 0.35 U/kg/week. We analyzed 37 studies involving 1788 patients that utilized a GH dose of <0.35 U/kg/week (low dose), and 11 studies involving 443 patients that utilized a GH dose of ≥0.35 U/kg/week (high dose), and find that a high dose of GH results in a significantly greater effect on FS compared to low dose GH (P = 0.012) (Supplementary Table 2 ).
Effect of Gender
In order to define the effects of gender, we performed meta-analysis using a cutoff of 50% of females in any given study. Using these criteria, we analyzed 30 studies involving 1713 patients with <50% females and 18 studies involving 518 patients with ≥50% females, and find no significant differences between variables as a function of gender (Supplementary Table 3 ).
Effect of Treatment Duration
To compare the effects of GH as a function of treatment duration, we meta-analyzed studies using a cutoff of 6 months duration (Supplementary Table 4) . We included 10 studies involving 176 patients of <6 months duration and 38 studies involving 2055 patients of ≥6 months duration. We observe a significantly greater negative effect of GH administration on BMI (P = 0.03) in patients treated for ≥6 months.
Effect of Age
To compare the effects of GH as a function of subject age, we meta-analyzed studies using a cutoff of 40 years of age in order to have sufficient data for analysis in both groups. Using this criterion, we included 14 studies involving 819 patients <40 years old and 34 studies involving 1412 patients ≥40 years old. We find no significant differences between variables as a function of age (Supplementary Table 5 ).
Discussion
Growth hormone has been used for treatment of GHD since 1958, when it was first purified from human pituitary glands. In the 1980s, recombinant GH became available and permitted widespread treatment of GHD, prompting study of the GHD population [8] . Since the most recent meta-analysis that evaluated CV, carbohydrate, and lipid parameters, numerous randomized, controlled studies evaluating the effects of GH have been published. Our goal was to update the literature with regards to the GH effect in the above parameters through eta-analysis of randomized, controlled trials. m 
Growth Hormone Serum Effects
In most included studies baseline IGF-1 and IGFBP3 levels were <100 ng/mL, with a significant increase in serum IGF-1 levels of ~81 ng/mL after GH administration ( Table 2) . This is in line with prior data, which demonstrate a 1-3 fold increase in IGF-1 levels after 6 -12 months of GH therapy [24, 25, 30, 32, 33] . GH therapy is also associated with increased serum insulin binding protein levels, specifically IGFBP3, which is in line with our findings [71, 72] . However, the effects of GH on levels of other IGFBPs are not well established and of studies that have evaluated the relationship between GH and these other IGFBPs, no correlation has been observed [42, 73] .
Anthropomorphic and CV Effects
GHD in adults is associated with increased vascular mortality rates [19, 22] . Previous studies have attributed this trend to adverse effects on anthropomorphic and CV parameters such as increased total cholesterol, LDL, WHR, and adiposity and decreased HDL [3, 7, 19, 32] . In our analysis, we observed improvement in several of these parameters after GH administration, with increases in both LBM and FFM, and a decrease in the WHR. No significant change in body weight was found regardless of the modality used to assess these variables. Decreases in LDL, TChol, ApoB, and CRP, and an increase in HDL were also observed. Most studies that assessed these variables were 6 months long, with several of 12 months duration ( Table 1) [12, 18, 41, 46, 48, [52] [53] [54] 58, 59, 67] . Approximately half of the included studies find an increase in HDL (3 of 8) and/or decrease in LDL (5 of 9), whereas the majority of studies find a decrease in TChol (7 of 9), and no studies find a change in TG (7 of 7). Two studies found the decrease in LDL and total cholesterol to be transient, limited to the first 3 -12 months of therapy [31, 41] . We observe significant ESs for LDL, HDL, and TChol in our analysis, which coincides with the results of the most recent meta-analysis to evaluate serum lipids in the setting of GH administration, though in that study the change in HDL was not statistically significant [9] . Mechanistically, GH increases hepatic uptake of very low density lipoprotein (VLDL) cholesterol and this may decrease conversion of VLDL to LDL, potentially explaining the above effect [74] . The effect of GH treatment duration on serum lipids is a debated topic. We observed no significant differences in LDL, TChol, or HDL when assessing the effects of GH treatment duration. However this may be due to the lack of studies of longer than 12 months duration.
We find no change in SBP, DBP, HR, SV, LVM, or FS, and a small, but significant positive effect on the EAR resulting from increases in EAR in 2 studies [21, 25] .
These findings echo those of a prior meta-analysis for SBP, though a significant decrease in DBP was demonstrated in that study, which is not recapitulated in our study [9] . Other non-placebo controlled studies not included in this analysis have shown a statistically significant moderate increase in systolic and diastolic blood pressure secondary to GH treatment [75, 76] . These differences in effect on BP may be secondary to mechanism of measurement, specifically ambulatory monitoring vs. conventional sphygmomanometer. A recent controlled trial of GH administration using 0.26 U/kg/wk of GH demonstrated no changes in EAR, SV, or FS [59] . In contrast, an earlier study used 0.35 U/kg/wk of GH and demonstrated increases in EAR, SV, and FS [25] . Studies utilizing GH doses of 0.10 -0.20 U/kg/week demonstrated no changes in EAR or FS, supporting previous conclusions that the CV effects of GH are likely related to dose [44, 49] , which is also supported by the finding that acromegaly results in increased CV mortality [77] . Earlier studies using higher GH doses demonstrated increases in LVM and other echocardiographic indices of heart function [25, 78] , whereas more recent studies using lower GH doses demonstrate no changes in these indices, suggesting that lower dose GH regimens are safer for cardiac function [18, 24, 25, 79] . These data suggest that GH administration in low to moderate doses results in normalization of cardiac performance and may have cardioprotective effects in patients with GHD, who have a 1.9-fold increased risk of CV mortality [68] . Notably, GH has been shown to normalize nitric oxide production when administered to GHD individuals, suggesting a molecular mechanism for enhanced cardiac performance, as well as cardioprotection [26] . However a recent uncontrolled 12-month trial of GH treatment concluded that GH increases carotid intima media thickness (IMT), ultimately leading to an increased number of atherosclerotic plaques [80] . In our analysis, only one study included IMT as an endpoint, in which the result was not significant. Longer duration studies are necessary to determine whether these changes have an overall effect on CV mortality.
Carbohydrate Metabolism
GH therapy has been implicated in development of insulin resistance and type II diabetes [69] . Our data show that GH produces a significant increase in fasting insulin and fasting glucose, which is likely related to GH's insulin antagonizing effect [29, 69] . The incidence of diabetes among the studies we analyzed was variable, though no studies reported new diagnoses of diabetes as a result of GH administration despite reporting increases in fasting insulin and glucose levels that potentially signify insulin resistance. Notably, few studies discussed diabetes in the context of increased insulin and glucose levels, making it difficult to assess whether diabetes was affected by GH treatment.
Insulin resistance due to GH may be a transient effect that subsides within 3 -6 months of the onset of GH therapy, as normalization of insulin-mediated glucose disposal in the setting of persistently elevated fasting insulin and C-peptide levels after 3 months of GH treatment has been observed [81] . These results have been reproduced by others [23, 82] , and reports supporting the conclusion that GHD induces a state of insulin resistance that is then normalized by GH administration are also available [29, 83] . A recent study conducted over 4 years concluded that there was no evidence of increased DM incidence in GHD patients on GH treatment [84] . However, more recent studies have demonstrated a persistent state of insulin resistance through 6 months of GH treatment that is linked to a switch from glucose clearance to lipid oxidation [45] . In addition, we find a small, significant increased effect on HgbA1c, which further supports a role for persistent dysregulation of glucose metabolism by GH. Given that most studies of GH administration do not go past 18 months, the long-term effects of GH administration on glucose metabolism bear additional study, particularly in the setting of a 6-fold increase in type 2 diabetes in children treated with GH [69] .
Safety
The long-term safety of GH administration remains unclear, as most studies evaluate the safety profiles of GH administration over only 6 -18 months. Lower dose GH therapy appears to be safer in the short term from the CV perspective, as described above, although the long-term CV and stroke risk in GH-treated patients remains unknown. A recent observational study in 281 patients with ischemic stroke demonstrated a minimal contribution of GH to the risk of poor functional outcome and death in these patients [85] . However, a study in female rats demonstrated that low IGF-1 levels increased the contribution of estrogen to ischemic stroke risk, suggesting that GHD may contribute to stroke risk in humans [86] . In addition, no controlled studies exist examining the use of GH with anabolic steroids in individuals without GHD, and thus the safety and efficacy of GH use in this population remains unclear [87] . Our study was unable to effectively assess adverse effects of GH treatment, as only 5 of the 48 studies utilized included such data.
Study Limitations
While this meta-analysis attempted to account for possible variations in effect size through an assessment of treatment duration, GH treatment dose, gender, and age, one important factor that is missing is the onset of GHD.
Previous studies have observed differences in IGF-1 level and response between childhood and adult onset GHD subjects, specifically that childhood onset GHD adults have a lower baseline IGF-1 level and a greater improvement in quality of life [88, 89] . However in our analysis, only 3 studies included information on timing of GHD onset [27, 47, 56] ; this subject was therefore not included in the subgroup analysis.
Future Directions
Our data argue that GH treatment in the setting of GHD results in positive changes in anthropomorphic indices, as well as beneficial changes in CV parameters. However the long-term risk of stroke and myocardial infarction rates related to GH administration are unknown and will need to be determined in future studies. While GH therapy appears to negatively affect insulin and glucose metabolism, whether this results in development of diabetes mellitus remains an unanswered question. Furthermore, no safety or efficacy data are available for GH administration in the non-GHD population, and very limited data exist on the interaction between GH and testosterone. Finally, while the risk of malignancy resulting from GH administration appears low, the true long-term effects of GH therapy on malignancy need to be further elucidated, and multiple additional populations assessed. Further work should focus on these unanswered questions with regard to GH administration.
Conclusion
GH treatment in GHD adults results in beneficial effects on total cholesterol, LDL, HDL, ApoB, CRP, LBM, FFM and WHR. As expected, GH reduces insulin sensitivity with increases in fasting insulin, fasting glucose and HgbA1C. Data on long-term safety, including on CV effects, insulin sensitivity and malignancy, as well as data assessing the role of GH replacement in combination with testosterone replacement needs to be assessed in larger, long-term trials.
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